Opendata, web and dolomites


Boosting productivity and performance in drug discovery with SEQUOIA - Semantic Query of Information Assets

Total Cost €


EC-Contrib. €






Project "SEQUOIA-DD" data sheet

The following table provides information about the project.


Organization address
address: 33 LUDGATE HILL
postcode: B3 1EH
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Project website
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.2.1.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT))
2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-09-01   to  2017-02-28


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 


 Project objective

Synapse Information (UK) have developed a novel semantic web technology, SEQUOIA – Semantic Query of Information Assets – allowing users to rapidly question > 100 disparate data assets in a code-free spreadsheet environment. Having proved the core platform functionality within the financial sector, Synapse now seek to apply SEQUOIA to the field of drug discovery R&D.

New drugs are required urgently to treat cancers & other rare/neurological diseases. However, costs and timescales of drug development are huge due to high failure rates. A principle barrier is the lack of real time comparison of disparate datasets, which can identify causal correlations behind reactions throughout the R&D process. Building on the prototype kernel solution, SEQUOIA targets the many high performance silos of public online drug R&D data, enabling all researchers to semantically probe these ontologies against internal R&D. Synapse therefore aim to catalyse a strategic 10 - 100× productivity gain during the discovery phase to disrupt the €5.5 billion/yr drug discovery software market.

The overall project aims to: fulfil the further technical developments required to transfer SEQUOIA into priority sectors within drug R&D; initiate the technical and commercial partnerships with key stakeholders in the pharmaceutical industry; validate performance through extended field trials; establish regulatory compliance; deliver compatibility with key user data environments; and optimise a developed product.

The proposed Phase 1 feasibility study seeks to address these requirements through: delivery of an elaborated business plan; prioritised EU market entry strategy; analysis of market-held data assets, technical development roadmap; engagement of key stakeholders in the pharmaceutical industry; supply chain initiation; development of IP strategy and value model; as well as regulatory and legal roadmaps for the final phase of developments and exploitation.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SEQUOIA-DD" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SEQUOIA-DD" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.1.;H2020-EU.2.3.1.)

Starcounter (2017)

In-Memory Computing and Artificial Intelligence Platform for Building Next Generation Enterprise Software

Read More  

scanvid (2017)

ScanVid - One-Click Integrated Access to Product-related Digital Content

Read More  

oWBI (2018)

Osmotic Wearable Bolus Injector (oWBI) for viscous drug delivery

Read More